MabVax Therapeutics Holdings (MBVX) Is Up Sharply On License Agreement

MabVax Therapeutics Holdings (MBVX) announced Monday morning that it has signed an asset purchase and license agreement with Boehringer Ingelheim.

MabVax Therapeutics gapped open sharply higher this morning and is now up 1.75 at $2.34 on the highest volume of the year. The stock has broken out to over a 4-month high.

by RTTNews Staff Writer

Source: Read Full Article